Quick Take
Freeline Therapeutics Holdings plc (FRLN) intends to raise $125 million from the sale of ADSs representing underlying common stock in an IPO, according to an amended registration statement.
The company is advancing a pipeline of treatment candidates for hemophilia, Gaucher disease and Fabry disease.
FRLN has produced promising trial results to-date and an IPO valuation within range, so for life science investors with an 18 - 36-month hold time frame, the IPO may be worth a closer look.
Company & Technology
Hertfordshire, UK-based Freeline was founded to develop its AAV-based